ECYT
Endocyte, Inc. Common Stock
ECYT
ECYT
Delisted
ECYT was delisted on the 20th of December, 2018.
63 hedge funds and large institutions have $11.9M invested in Endocyte, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 28 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
63
Holders Change
-12
Holders Change %
-16%
% of All Funds
1.57%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
10
Reduced
28
Closed
16
Calls
$108K
Puts
$542K
Net Calls
-$434K
Net Calls Change
-$124K
Top Buyers
| 1 |
D.E. Shaw & Co
New York
|
$588K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
$2.12M |
| 3 |
ZIM
Zacks Investment Management
Chicago,
Illinois
|
$136K |
| 4 |
Renaissance Technologies
New York
|
$292K |
| 5 |
Two Sigma Investments
New York
|
$97K |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
$3.45M |
| 2 |
PA
Pinnacle Associates
New York
|
$46K |
| 3 |
Goldman Sachs
New York
|
$16K |
| 4 |
Morgan Stanley
New York
|
$241K |
| 5 |
Millennium Management
New York
|
$637K |
